Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors

Lung cancer is a major cause of cancer-related deaths. Alectinib is the first line of treatment for patients with ALK-positive lung cancer, but the survival rate beyond 2–3 years is low. Co-targeting secondary oncogenic drivers such as SHP2 is a potential strategy for improving drug efficacy. This i...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, M. A., Bland, A. R., Ashton, J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281967/
https://www.ncbi.nlm.nih.gov/pubmed/37339995
http://dx.doi.org/10.1038/s41598-023-37006-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281967/
https://www.ncbi.nlm.nih.gov/pubmed/37339995
http://dx.doi.org/10.1038/s41598-023-37006-2

Ejemplares similares